Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial
Heikki Joensuu(Orion Corporation (Finland)), Pirkko‐Liisa Kellokumpu‐Lehtinen, Leena Helle(Kotka Maritime Research Centre), R. Kokko, Tapio Utriainen(Helsinki University Hospital), Päivi Auvinen(University of Eastern Finland), Kari Möykkynen(Tampere University), Hannu Leinonen(Helsinki University Hospital), Vesa Kataja(Kuopio University Hospital), Seija Ingalsuo(Vaasa Central Hospital), Tapio Salminen(Tampere University Hospital), Tuomo Alanko, Jorma Isola(Tampere University Hospital), Mauri Huusko(Tampere University), Sirkku Jyrkkiö(Turku University Hospital), R. Asola(Satakunta Central Hospital), Marjo Pajunen(Central Finland Health Care District), Taina Turpeenniemi‐Hujanen(Oulu University Hospital), Mika Leinonen, Petri Bono(Helsinki University Hospital)
Cited by 459
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k